比格犬体内FGFC1药物代谢动力学特征及组织分布的研究

摘要

Aim To detect the concentration of the no-vel marine fibrinolytic compound FGFC1 ( fungi fi-brinolytic compound 1 ) on Beagle dogs ’ plasma and tissue by high performance liquid chromatography ( HPLC) , and also to investigate the pharmacokinetics and tissue distribution in Beagle dogs with intravenous injection, and to evaluate the FGFC1 into medicinal. Methods Chromatographic column: HP-C18 ( 4. 6 mm × 250 mm,5 μm); the column temperature was 40℃;the mobile phase was acetonitrile -0. 1% triflu-oroacetic acid gradient elute, the flow rate of 1 mL· min-1; the ultraviolet detection wavelength was 265 nm. The dog plasma samples were collected at different intervals after intravenous injection of three different doses (7. 5, 5. 0, 2. 5 mg·kg-1 ) of FGFC1, and the concentration of FGFC1 in plasma and tissue was deter-mined by HPLC method for estimating pharmacokinetic parameters and tissue distribution. Results The pa-rameters of 7. 5, 5. 0, 2. 5 mg·kg-1 were as follows:its elimination half-life ( T1/2β) was ( 49. 035 ± 2. 171 ) , ( 48. 422 ± 2. 113 ) and ( 48. 811 ± 2. 372 ) min, respectively;the peak concentration was (56. 48 ± 6. 23 ) , ( 48. 63 ± 5. 53 ) , ( 13. 64 ± 2. 76 ) mg · L-1 , respectively;clearance rate ( CL ) was ( 0. 0062 ± 0. 0004 ) , ( 0. 0071 ± 0. 0008 ) and ( 0. 0092 ± 0. 0006) L·min-1 ·kg-1 , respectively; mean reten-tion time ( MRT ) was ( 28. 17 ± 1. 16 ) , ( 26. 23 ± 0. 35) and (28. 66 ± 0. 84) min, respectively. Tissue distribution revealed that FGFC1 could quickly distrib-uted into the heart, liver, spleen, lung, kidney, intes-tine, stomach, brain, intestine, testicle, urine and fe-ces. Interestingly, the highest drug (FGFC1) concen-tration level was detected in the liver. Conclusions The above study shows a good pharmacokinetic profile as well as a good tissue distribution, indicating a drug-gable nature of the structure. Therefore, we consider that FGFC1 is promising for further study.%目的用高效液相色谱法( HPLC)对海洋新型纤溶化合物FGFC1(fungi fibrinolytic compound 1)的药物代谢动力学和组织分布进行成药性的初步评价。方法分析柱HP-C18柱(4．6 mm ×250 mm,5μm)；柱温为40℃；流动相为乙腈-水(0．1%三氟乙酸)45∶55(V/V)和85∶15(V/V),流速1 mL·min-1；检测波长265 nm。前肢静脉给予比格犬3种剂量(7．5、5．0、2．5 mg·kg-1)的FGFC1,于不同的时间点取血,用HPLC测定血浆和组织中FGFC1的浓度并计算其药物代谢动力学参数和组织分布情况。结果 FGFC1的消除半衰期( T1/2β)分别为(49．035±2．171)、(48．422±2．113)及(48．811±2．372) min；达峰浓度 Cmax分别为(56．48±6．23)、(48．63±5．53)、(13．64±2．76) mg·L-1；机体总消除率(CL)分别为(0．0062±0．0004)、(0．0071±0．0008)、(0．0092±0．0006) L·min-1·kg-1；平均保留时间(MRT)分别为(28．17±1．16)、(26．23±0．35)、(28．66±0．84) min。组织分布研究结果表明FGFC1在静脉给药后迅速分布到全身各处,最高药物浓度水平在肝脏中检出。结论FGFC1在比格犬体内呈现良好的药代动力学特性和组织分布特点,表现出较高的成药性特征,值得进一步研究。